Genentech received approval from the Food and Drug Administration to market Actemra, or tocilizumab, for children age 2 and older with active polyarticular juvenile idiopathic arthritis. The drug, a humanized interleukin-6 receptor antagonist, can be given alone or with methotrexate. The approval was based on data from a late-stage trial showing that the drug improved symptoms in children with the condition.

Related Summaries